company background image
CATX logo

Perspective Therapeutics NYSEAM:CATX Stock Report

Last Price

US$1.20

Market Cap

US$704.2m

7D

0%

1Y

110.5%

Updated

27 Mar, 2024

Data

Company Financials +

Perspective Therapeutics, Inc.

NYSEAM:CATX Stock Report

Market Cap: US$704.2m

CATX Stock Overview

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally.

CATX fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Perspective Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Perspective Therapeutics
Historical stock prices
Current Share PriceUS$1.20
52 Week HighUS$1.36
52 Week LowUS$0.20
Beta1.53
1 Month Change33.33%
3 Month Change163.74%
1 Year Change110.53%
3 Year Change10.09%
5 Year Change223.28%
Change since IPO20.00%

Recent News & Updates

Recent updates

We're Interested To See How Isoray (NYSEMKT:ISR) Uses Its Cash Hoard To Grow

Mar 19
We're Interested To See How Isoray (NYSEMKT:ISR) Uses Its Cash Hoard To Grow

Shareholder Returns

CATXUS BiotechsUS Market
7D0%0.9%0.4%
1Y110.5%10.3%28.8%

Return vs Industry: CATX exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: CATX exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is CATX's price volatile compared to industry and market?
CATX volatility
CATX Average Weekly Movement20.0%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: CATX's share price has been volatile over the past 3 months.

Volatility Over Time: CATX's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
199891Thijs Spoorhttps://www.perspectivetherapeutics.com

Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facilities or physician practices that utilize various surgical facilities.

Perspective Therapeutics, Inc. Fundamentals Summary

How do Perspective Therapeutics's earnings and revenue compare to its market cap?
CATX fundamental statistics
Market capUS$704.16m
Earnings (TTM)-US$29.01m
Revenue (TTM)US$6.31m

111.6x

P/S Ratio

-24.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CATX income statement (TTM)
RevenueUS$6.31m
Cost of RevenueUS$5.98m
Gross ProfitUS$326.00k
Other ExpensesUS$29.34m
Earnings-US$29.01m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.049
Gross Margin5.17%
Net Profit Margin-459.89%
Debt/Equity Ratio1.8%

How did CATX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.